RECENT NEWS

The date and venue for next year's British Society for Microbial Technology (BSMT) Annual Microbiology Conference are now confirmed as Thursday 13 May 2027 at the Royal Air Force Museum in Hendon, North London.

A new report from The Royal College of Pathologists (RCPath) highlights serious forensic pathology workforce issues. Forensic Pathology Workforce 2026 shows how the mixed model of service delivery and employment models across the UK contributes to geographic inequity in vacancies and restricted training opportunities.

Proscia has received a new 510(k) clearance from the US Food and Drug Administration (FDA) for Concentriq AP-Dx. The clearance includes compatibility with the Leica Aperio GT 450 DX slide scanner, cloud deployment, and a Predetermined Change Control Plan (PCCP).

The NHS is to invite half a million men who have had or are living with prostate cancer to join a major research programme to improve early detection and treatment of the condition.

The Institute of Biomedical Science (IBMS) has published a new positioning paper calling for the controlled, independently evaluated implementation of AI-assisted digital cytology within NHS cervical screening programmes.

Tens of thousands of young people have received the first of a life-saving double dose of the meningitis B vaccine within just two weeks of the NHS launching its biggest ever catch-up campaign for the virus.

The Medical Research Council (MRC) has invested £50 million into the study of mitochondrial diseases to improve treatments.

POCT Innovators’ next Power to Disrupt one-day event takes place in Oxford on Monday 16 November, and booking is open now, with free places on offer to NHS workers.

A pioneering pathology technology developed by the National Pathology Imaging Co‑operative (NPIC) is set for international deployment after securing a commercial agreement with precision cancer diagnostics firm Epredia.

In May, over 100 delegates and representatives from 21 commercial companies descended on the Royal Air Force Museum in Hendon, North London for the 41st iteration of the British Society for Microbial Technology (BSMT) Annual Microbiology Conference.

The development of artificial intelligence in medical technology is usually discussed as a technical challenge. For companies attempting to bring AI-enabled medical devices to market, however, further constraints are becoming increasingly important.

illumiSonics, a medical technology company commercialising label-free tissue imaging, has launched a prospective clinical validation study at Sunnybrook Health Sciences Centre evaluating its Multi-Laser Imaging (MLI) platform for skin cancer margin assessment during Mohs micrographic surgery.

Epredia, a global leader in precision cancer diagnostics solutions, has announced an agreement with Canada-based manufacturer Lab Improvements to bring intelligent archiving for tissue samples to US pathology laboratories.

One Biosciences, a company pioneering clinical-grade single-cell tumour profiling, has announced data establishing that single-cell RNA expression profiles can be generated from standard, formalin-fixed paraffin wax-embedded (FFPE) pathology specimens obtained in routine cancer care using its proprietary platform OneMap.

bioAffinity Technologies has announced a collaboration with Pictor to support development and commercialisation of bioAffinity Technologies’ next-generation diagnostic tests designed to provide a more complete picture of lung inflammation in patients with asthma and chronic obstructive pulmonary disease (COPD).

The Institute of Tropical Medicine (ITM) in Antwerp is receiving an additional €2 million in funding from the Belgian Directorate-General for Development Cooperation and Humanitarian Aid (DGD) to strengthen research and control efforts against the mpox virus (pictured) in the Democratic Republic of the Congo (DRC).

Submissions for Lab Innovations’ Lab Awards, which recognise the achievements and successes of individuals, laboratories and suppliers over the past year, remain open until August 14.

Molecular diagnostics firm Cepheid will unveil the third generation of the GeneXpert system at the upcoming Association for Diagnostics & Laboratory Medicine (ADLM) Annual Scientific Meeting.

En Carta Diagnostics has raised €5 million in financing to fund regulatory certification, industrialisation and commercial launch in Europe and the US of its at-home molecular diagnostics.

Researchers at Loughborough University are uncovering new evidence that exercise may help counteract the cancer-promoting effects of fat cells. The research uses advanced 3D cell culture models and bioluminescence-based assay technology from Promega to generate physiologically relevant data that traditional 2D culture models cannot replicate.